Solid Tumor Clinical Trials

A listing of Solid Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2017 clinical trials
Featured trial
Study of INCB123667 in Subjects With Advanced Solid Tumors

monotherapy at the RDE(s) in participants with selected advanced or metastatic solid tumors. Part 1A (dose escalation) will determine the recommended dose of INCB123667 for expansion (RDE) and the maximum

  • 0 views
  • 10 May, 2022
Featured trial
Study of INCA 0186 in Subjects With Advanced Solid Tumors

preliminary efficacy of INCA00186 when given alone or in combination with INCB106385 and/or retifanlimab in participants with specific advanced solid tumors; squamous cell carcinoma of the head and neck

  • 0 views
  • 17 May, 2022
  • 6 locations
Featured trial
A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been

solid tumors
solid tumor
  • 84 views
  • 10 May, 2022
  • 53 locations
Featured trial
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors Carcinoma

The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.

cancer
solid tumors
  • 55 views
  • 10 May, 2022
  • 9 locations
Featured trial
ATR Inhibitor BAY 1895344 plus pembrolizumab in advanced solid tumors (GI, Pancreatic, mCRPC, NSCLC)

This clinical study aims to investigate if impairment of the deoxyribonucleic acid damage repair (DDR) pathway by the Elimusertib in combination with blockade of the PD-1/PD-L1 pathway by pembrolizumab, may improve antitumor responses in advanced cancer patients with DDR aberrations, at an acceptable safety profile and an expected positive benefit/risk …

EGFR
measurable disease
pembrolizumab
  • 20 views
  • 13 Oct, 2021
  • 8 locations
Featured trial
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.  

solid tumors
cancer
solid tumor
measurable disease
metastatic cancer
  • 38 views
  • 10 May, 2022
  • 13 locations
Featured trial
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 (formerly MGA012) in Patients with Advanced Solid Tumors

INCMGA00012 administered IV every two or four weeks in patients with relapsed/refractory, unresectable locally advanced or metastatic solid tumors.  The study consists of two phases, a Dose

primary cancer
cancer
endometrial carcinoma
measurable disease
  • 295 views
  • 10 May, 2022
  • 17 locations
Featured trial
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor

malignancies
administration intravenous
FGFR3
solid tumor
FGFR1
  • 112 views
  • 10 May, 2022
  • 50 locations
Featured trial
VastBiome: The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may prove to be beneficial in promoting anti-tumor immune responses. However, large prospective studies in humans with longitudinal sample collection and standardized methods …

cancer chemotherapy
cancer
programmed cell death 1 ligand 1
targeted therapy
  • 0 views
  • 28 Feb, 2022
  • 1 location
Featured trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With MTAP Homozygous Deletion

This is a Phase 1/2, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor

measurable disease
  • 0 views
  • 19 Apr, 2022
  • 3 locations